Loading market dashboard
INmune Bio, Inc.
INMBHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
XPro1595 showed a highly significant treatment effect in the full mITT population (p=0. 0028; d=0. 46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect. Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.
XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.
Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing therapies that target innate immune dysfunction, today announced that results from its Phase 2 MINDFuL trial in Alzheimer's disease have been published in the peer-reviewed journal NPJ Dementia. The study evaluated the safety, biomarker engagement, and clinical efficacy of XPro™ (XPro1595, pegipanermin) in patients with mild Alzheimer's disease characterized by biomarkers of inflammation. In a pre-specified analysis of the protocol-defined Alzheimer's Disease with inflammation (ADi) subgroup, XPro™ showed directionally consistent benefit across cognitive, global, functional, behavioral, and biomarker endpoints over 24 weeks, with no amyloid-related imaging abnormalities (ARIA) observed.
BOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to XPro™ (pegipanermin), the company's first-in-class selective soluble TNF inhibitor, for the treatment of early Alzheimer's disease (AD). The designation specifically covers XPro™ for treatment of early Alzheimer's disease encompassing both mild cognitive impairment (MCI) due to AD and mild Alzheimer's disease dementia, which represents a large and growing population.
Alliance launches with 26 founding companies to develop a national strategy for U.S. biotechnology leadership BOCA RATON, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- INmune Bio, a clinical-stage biotechnology company developing treatments that harness the patient's innate immune system to fight disease, today announced it has been named a founding member of the American Biotech Innovation Alliance (ABIA).
INmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks Transcript
BOCA RATON, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2026 and provides a business update.
LONDON, UK and BOCA RATON, FL, May 05, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune Bio”), a clinical-stage biotechnology company, and Anthony Nolan, a pioneering UK-based charity that set up the world's first stem cell register and is now driving forward cell therapy advancements, today announced the signing of an amended and restated Material Transfer and License Agreement. This expanded collaboration secures the long-term provision of high-quality umbilical cord tissue to power INmune Bio's CORDStrom™ platform, the industry's most advanced Mesenchymal Stromal Cell (MSC) technology designed to deliver consistent, scalable, and "off-the-shelf" cellular therapies which are suitable for supply in UK, EU and US, as well as other global regions.
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday, May 7th, 2026 at 4:30pm EDT to discuss results for its quarter ended March 31, 2026 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday, May 7th, 2026 at 4:30pm EDT to discuss results for its quarter ended March 31, 2026 and to provide a corporate update.
BOCA RATON, Fla. , April 16, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage biotechnology company focused on developing therapies that harness the patient's innate immune system, today announces new preclinical data for INB03 (XPro1595 for oncology).
Shares of INmune Bio, Inc. (NASDAQ: INMB - Get Free Report) have been assigned a consensus rating of "Hold" from the six brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has
INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript
BOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announces its financial results for the year ended December 31, 2025 and provides a business update.
